Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response / Edition 1

Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response / Edition 1

by Federico Innocenti
     
 

ISBN-10: 1588296466

ISBN-13: 9781588296467

Pub. Date: 10/17/2008

Publisher: Springer-Verlag New York, LLC

The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to

…  See more details below

Overview

The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In "Pharmacogenomics, Anticancer Drug Discovery, and Response," edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

Product Details

ISBN-13:
9781588296467
Publisher:
Springer-Verlag New York, LLC
Publication date:
10/17/2008
Series:
Cancer Drug Discovery and Development Series
Edition description:
2009
Pages:
378
Product dimensions:
7.70(w) x 10.30(h) x 1.00(d)

Table of Contents

pharmacoGENOMICS, ANTICANCER DRUG DISCOVERY, AND RESPONSE

Book editor: Federico Innocenti, M.D., Ph.D.

Genomic experimental approaches in oncology

  1. Toward the realisation of the promise of microarrays in oncology
  2. Neil Winegarden

  3. Cell based models to identify genetic variants contributing to anticancer drug response
  4. M. Eileen Dolan

  5. Proteomic analysis in cancer patients
  6. Kazuyuki Nakamura

  7. MicroRNAs and discovery of new targets
  8. Gozoh Tsujimoto

  9. Pharmacogenomics of the National Cancer Institute’s 60 tumor cell panel
  10. David G. Covell

  11. Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers

Kwong-Kwok Wong

Pharmacogenomics of toxicity and response of chemotherapy

  1. Concordance between tumor and germline DNA
  2. Sharon Marsh

  3. Epidermal growth factor receptor mutations and sensitivity to selective kinase inhibitors in human lung cancer

Jeffrey Settleman

3. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients

Mark Litzow

  1. Role of thymidylate synthase gene variations in colorectal cancer patients
  2. Heinz-Josef Lenz

  3. Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-methyltransferase gene
  4. Martin Stanulla

  5. The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies
  6. Dong Hwan Kim

  7. DNA repair and mitotic check point genes as potential predictors of chemotherapy response in non-small-cell lung cancer
  8. Rafael Rosell

  9. Dihydropyrimidine dehydrogenase (DPYD) gene polymorphism: portrait of a serial killer.
  10. Gerard Milano

  11. Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment
  12. Kimie Sai

  13. Microarray profiling in breast cancer patients

Lan Guo

11. Role of the folate pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response

Richard Aplenc

Pharmacogenomics in clinical drug development in oncology

  1. Pharmacogenomics in drug development: an pharmaceutical industry perspective
  2. Tal Zaks

  3. Identification of a pharmacogenomic biomarker classifiers in cancer drug development
  4. Richard Simon

  5. Toxicogenomics application to oncology drug development
  6. Teresa Lettieri

  7. Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches

Xifeng Wu

Read More

Customer Reviews

Average Review:

Write a Review

and post it to your social network

     

Most Helpful Customer Reviews

See all customer reviews >